Get started
Author

P. G. Hoff

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123
2026 · Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, et al. · npj Breast Cancer · 2
PDF
Abstract PS4-07-04: Rare but Resistant: Neoadjuvant Chemoimmunotherapy in Special Histological Subtypes of Triple-Negative Breast Cancer — Insights from the Neo-Real/GBECAM-0123 Study
2026 · R. Barroso-Sousa, L. Testa, et al. · Clinical Cancer Research · 1
Role of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer treated with KEYNOTE-522 in real-world setting
2026 · Renata Colombo Bonadio, Flávia Cavalcanti Balint, et al. · npj Breast Cancer
PDF
Differential response and survival across rare histologic subtypes of triple-negative breast cancer following neoadjuvant chemo-immunotherapy
2026 · Romualdo Barroso-Sousa, Mariana Carvalho Gouveia, et al. · npj Breast Cancer
PDF
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort
2026 · Monique Celeste Tavares, Flávia C. Balint, et al. · npj Breast Cancer
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study
2026 · Matheus de Oliveira Andrade, Renata Colombo Bonadio, et al. · Breast Cancer Research and Treatment
Abstract PS4-07-11: Analysis of patients with triple-negative breast cancer and germline BRCA mutation undergoing neoadjuvant treatment following the keynote 522 protocol in real-world. Insights from the Neo-Real/GBECAM-0123 Study
2026 · M. C. Tavares, F. C. Balint, et al. · Clinical Cancer Research
Abstract PS2-02-17: The High Unmet Need of Patients with Early Relapse After the KEYNOTE-522 Regimen - Evidence from the Neo-Real/GBECAM-0123 Study
2026 · R. Colombo Bonadio, L. Lapuchesky, et al. · Clinical Cancer Research
Abstract PS4-07-10: The Relationship Between Tumor-Infiltrating Lymphocytes (TILs), Pathologic Complete Response, and Event-Free Survival in Patients with Early-Stage Triple-Negative Breast Cancer Treated with KEYNOTE-522 regimen in a Real-World Scenario
2026 · R. C. Bonadio, M. C. Tavares, et al. · Clinical Cancer Research
Abstract PS1-02-10: Knowledge and adherence to exercise recommendations among oncologic patients
2026 · R. C. Cangussu, L. Andrade, et al. · Clinical Cancer Research
Real-world Data on the Use of Immunotherapy for Triple-negative Breast Cancer
2022 · Marina Nishimuni, Luciana Campi Auresco, et al. · Brazilian Journal of Oncology
Immunoscore as a Predictor of Recurrence in Stage Iii Colon Cancer
2022 · Renata Colombo Bonadio, Fernando Soares, et al. · Brazilian Journal of Oncology
Does the Gram-negative Bacteria Colonization Impact on the Risk of Develop Infection by Those Organisms During Neutropenia?
2017 · Renata P Romi, Maristela Freire, et al. · Open Forum Infectious Diseases
Works count: 13
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type